Molecular genetic heterogeneity in undifferentiated endometrial carcinomas
Modern Pathology 29, 1390-1398 (November 2016) | doi:10.1038/modpathol.2016.132
High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas
implications for tumor clonal evolution and treatment Modern Pathology 29, 1347-1357 (November 2016) | doi:10.1038/modpathol.2016.133
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer
Modern Pathology 29, 1292-1305 (November 2016) | doi:10.1038/modpathol.2016.134
Prostate Cancer Grading
A Decade After the 2005 Modified Gleason Grading System Arch Pathol Lab Med – Special Article – 2016. pp 1 – 13.
ІІ МАКЕДОНСКИ КОНГРЕС ПО ПАТОЛОГИЯ – ПРОГРАМА
ІІ МАКЕДОНСКИ КОНГРЕС ПО ПАТОЛОГИЯ – ПРОГРАМА
ESP Newsletter Summer Edition 2016
This publication, in an attempt to reflect the polytonal vibrancy of European pathology, has come to include a variety of sections and an increasing number of pages. ESP Newsletter Summer Edition 2016 is here!
Благодарствено писмо до Медицински Университет Варна
Във връзка с проведеното Европейско училище по патология в Медицински университет – Варна, 6-8 юни 2016 г., организационният екип изказва своите благодарности към всички допринесли за осъществяването на курса.
European School of Pathology, Varna 2016
June 6-8, 2016 in Varna took place European School of Pathology – Update in Thyroid Pathology for Pathologist. The course is designated for (two days and half) with European CME Credits – 20 (ECMEC)
The pro-apoptotic role of autophagy in breast cancer
Background: Autophagy is a catabolic process that has a vital role in cancer progression and treatment. Current chemotherapeutic agents, which target autophagy, result in growth inhibition in many cancer types. In this study, we examined the role of autophagy in breast cancer (BCa) patients as well as BCa cell lines. Methods: Tissue microarray was used to detect the expression of an autophagy marker, LC3B in BCa patients (normal/ hyperplasia ¼ 8; grade-I ¼ 15, grade-II ¼ 84, and grade-III ¼ 27)…
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Abstract Purpose: The intratumoural heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in gastric cancer is a major challenge when identifying patients who might benefit from HER2-targeting therapy. We investigated the significance of reevaluation of HER2 status in primary sites and metastatic or recurrent sites in advanced gastric cancer patients whose primary tumours were initially HER2-negative. Full article in pdf format.